![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Christopoulos, Petros; Kluck, Klaus; Kirchner, Martina; Lueders, Heike; Roeper, Julia; Falkenstern-Ge, Roger-Fei; Szewczyk, Marlen; Sticht, Florian; Saalfeld, Felix C.; Wesseler, Claas; Hackanson, Bjoern; Dintner, Sebastian; Faehling, Martin; Kuon, Jonas; Janning, Melanie; Kauffmann-Guerrero, Diego; Kazdal, Daniel; Kurz, Sylke; Eichhorn, Florian; Bozorgmehr, Farastuk; Shah, Rajiv; Tufman, Amanda; Wermke, Martin; Loges, Sonja; Brueckl, Wolfgang M.; Schulz, Christian; Misch, Daniel; Frost, Nikolaj; Kollmeier, Jens; Reck, Martin; Griesinger, Frank; Grohe, Christian; Hong, Jin-Liern; Lin, Huamao M.; Budczies, Jan; Stenzinger, Albrecht und Thomas, Michael
(2022):
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
In: European Journal of Cancer, Bd. 170: S. 106-118
Brueckl, Wolfgang M.; Reck, Martin; Rittmeyer, Achim; Kollmeier, Jens; Wesseler, Claas; Wiest, Gunther H.; Christopoulos, Petros; Stenzinger, Albrecht; Tufman, Amanda; Hoffknecht, Petra; Ulm, Bernhard; Reich, Fabian; Ficker, Joachim H. und Laack, Eckart
(2021):
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
In: Translational Lung Cancer Research, Bd. 10, Nr. 7: S. 3093-3106
Brückl, Wolfgang M.; Reck, Martin; Rittmeyer, Achim; Kollmeier, Jens; Wesseler, Claas; Wiest, Gunther H.; Christopoulos, Petros; Tufman, Amanda; Hoffknecht, Petra; Ulm, Bernhard; Reich, Fabian; Ficker, Joachim H. und Laack, Eckart
(2020):
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
In: Clinical Medicine Insights-Oncology, Bd. 14: S. 1-9
[PDF, 433kB]
Thomas, M.; Ponce-Aix, S.; Navarro, A.; Riera-Knorrenschild, J.; Schmidt, M.; Wiegert, E.; Kapp, K.; Wittig, B.; Mauri, C.; Gomez, M. Domine; Kollmeier, J.; Sadjadian, P.; Froehling, K.-P.; Huber, R. M.; Wolf, M.; Pall, Georg; Surmont, Veerle; Bosquee, Leon; Germonpre, Paul; Brückl, Wolfgang; Grah, Christina; Herzmann, Christian; Leistner, Rumo; Meyer, Andreas; Müller, Lothar; Schmalz, Oliver; Scholz, Christian; Schröder, Michael; Serke, Monika; Wesseler, Claas; Brandts, Christian; Kopp, Hans-Georg; Blau, Wolfgang; Griesinger, Frank; Garcia Campelo, Maria Rosario; Garcia Garcia, Yolanda und Trigo Perez, Jose Manuel
(2018):
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
In: Annals of Oncology, Bd. 29, Nr. 10: S. 2076-2084